Collegium Pharmaceutical (COLL) Other Non-Current Assets (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Other Non-Current Assets of $1.1 million for Q1 2026, up 1.05% year-over-year from $1.0 million in Q1 2025, and little changed quarter-over-quarter from $1.1 million in Q4 2025.
Collegium Pharmaceutical (COLL) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 1.05% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 1.05% YoY), while the FY2025 annual figure was $1.1 million, down 87.38% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $8.4 million in Q4 2024, with the low at $740000.0 in Q3 2023.
- The 5-year median for Other Non-Current Assets is $2.3 million (2025), against an average of $2.3 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets surged 699.24% in 2024, then slumped 87.38% in 2025.
- Collegium Pharmaceutical's Other Non-Current Assets stood at $2.5 million in 2022, then sank by 58.89% to $1.0 million in 2023, then soared by 699.24% to $8.4 million in 2024, then plunged by 87.38% to $1.1 million in 2025, then grew by 0.19% to $1.1 million in 2026.
- Business Quant data shows COLL's Other Non-Current Assets at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Collegium Pharmaceutical | 892.67 Mn | 743.35 Mn | 110.29 Mn | 15.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.24 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 8.37 Mn |
| Sep 30, 2024 | 4.17 Mn |
| Jun 30, 2024 | 858,000.00 |
| Mar 31, 2024 | 954,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 740,000.00 |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.55 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 2.55 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | 2.55 Mn |